Company news: Elsevier, Abbott

Share this article:

Elsevier printed the inaugural issue of its Operations Research for Health Care journal in March. The company says the quarterly publication will help researchers, teachers and practitioners interested in research techniques for optimal healthcare delivery. The journal will include series of communications for clinicians, managers and decision makers.

Abbott Labs is one step closer to splitting into two. The company announced Wednesday that its research-based company will be named AbbVie when the pharma co divides into a medical products company named Abbott, and a research company at the end of this year. The Abb-plus name “connects the new company to Abbott and its heritage of pioneering science,” Richard Gonzalez, global pharmaceuticals EVP said in a statement. As AbbVie's chair and CEO, Gonzalez will oversee a portfolio that includes Humira, Lupron and Kaletra.

Amgen's new CEO Robert Bradway will get a $1.4 million raise when he takes his new job May 23. The bump amounts to a 36% increase over his current salary, and was announced along with an increase in target cash incentives for the company's executive vice presidents. Current CEO Kevin Sharer will stay on as Chairman of the Board through 2012 and will continue to be paid at his current salary.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.